Design (Docking and QSAR Studies) and synthesis of histone deacetylase 2 (HDAC2) inhibitors series

被引:7
|
作者
Martinez-Pacheco, Heidy [1 ]
Espinosa-Raya, Judith [2 ]
Picazo, Ofir [2 ]
Roldan-Roldan, Gabriel [1 ]
Vinas-Bravo, Omar [3 ]
Ramirez-Galicia, Guillermo [3 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Med, Dept Fisiol, Lab Neurobiol Conductual, Mexico City 04510, DF, Mexico
[2] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Plan San Luis & Salvador Diaz Miron S-N, Mexico City 11340, DF, Mexico
[3] Univ Papaloapan, Inst Quim Aplicada, Campus Tuxtepec,Circuito Cent 200,Parque Ind, Tuxtepec 68301, Oaxaca, Mexico
关键词
Rational design; QSAR studies; Docking studies; HDAC2; Cognitive impairment; MEMORY FORMATION; FEAR EXTINCTION; ACETYLATION; PHYSIOLOGY; DISEASE; CORTEX;
D O I
10.1007/s00044-017-2051-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In recent years, it has been shown that histone deacetylase 2 (HDAC2) inhibitors increase histone acetylation and enhance memory processes, probably due to an increase in the gene transcription rate that emerges during memory formation. Histone acetylation generally favors long-term memory, whereas histone deacetylation impinges on it. However, until today there is no specific drug that can target the HDAC2 active site. In this work we applied the method of rational drug design, through enzyme-structural-chemical properties to generate new molecules as HDAC inhibitors. By the application of Quantitative Structure-Activity Relationship (QSAR) and molecular modeling methodologies our aim is to predict more potent HDAC inhibitors. 76 small molecules with potential activity were analyzed using QSAR methodology. The best model was constructed by merging the properties of electronegativity, atomic mass, polarizability, van der Waals forces and some conformational aspects, with the following statistical parameters: r (2) = 0.8935, q(LOO-CV)(2) = 0.8498, and q(LGO-CV)(2) = 0.7598. The molecular docking of the ligands on the template was performed by blind docking. The results showed intermolecular interactions between small molecules and some amino acids, such as His145, His146, Asp179, Asp186, and internal-H2O and Zn2+ of which IN01, IN04, and IN14 showed theoretically better biological activity compared with that of TSA and SAHA. Mainly, the IN14 synthesized molecule is a theoretical inhibitor of HDAC class I.
引用
收藏
页码:206 / 223
页数:18
相关论文
共 50 条
  • [21] Histone deacetylase HDAC2 regulates microRNA-125a expression in neuroblastoma
    Liu, Denghui
    Tang, Xianglian
    Huang, Zhao
    Wen, Jiabing
    Zhou, Yuxiang
    BRAIN AND BEHAVIOR, 2022, 12 (02):
  • [22] HDAC2 deficiency and histone acetylation
    Ree, Anne Hansen
    Folkvord, Sigurd
    Flatmark, Kjersti
    NATURE GENETICS, 2008, 40 (07) : 812 - 813
  • [23] Decreased Histone Deacetylase 2 (HDAC2) in Peripheral Blood Monocytes (PBMCs) of COPD Patients
    Tan, Chunting
    Xuan, Lingling
    Cao, Shuhua
    Yu, Ganggang
    Hou, Qi
    Wang, Haoyan
    PLOS ONE, 2016, 11 (01):
  • [24] Computational identification of novel histone deacetylase inhibitors by docking based QSAR
    Nair, Syam B.
    Teli, Mahesh Kumar
    Pradeep, H.
    Rajanikant, G. K.
    COMPUTERS IN BIOLOGY AND MEDICINE, 2012, 42 (06) : 697 - 705
  • [25] Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
    Alsawalha, Murad
    Bolla, Srinivasa Rao
    Kandakatla, Naresh
    Srinivasadesikan, Venkatesan
    Veeraraghavan, Vishnu Priya
    Surapaneni, Krishna Mohan
    BIOINFORMATION, 2019, 15 (06) : 380 - 387
  • [26] HDAC2 deficiency and histone acetylation
    Anne Hansen Ree
    Sigurd Folkvord
    Kjersti Flatmark
    Nature Genetics, 2008, 40 : 812 - 813
  • [27] Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation
    Dovey, Oliver M.
    Foster, Charles T.
    Cowley, Shaun M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (18) : 8242 - 8247
  • [28] The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
    Krämer, OH
    Zhu, P
    Ostendorff, HP
    Golebiewski, M
    Tiefenbach, J
    Peters, MA
    Brill, B
    Groner, B
    Bach, I
    Heinzel, T
    Göttlicher, M
    EMBO JOURNAL, 2003, 22 (13): : 3411 - 3420
  • [29] Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
    Urias, Beatriz Silva
    Pavan, Aline Renata
    Albuquerque, Gabriela Ribeiro
    Prokopczyk, Igor Muccilo
    Ferreira Alves, Tania Mara
    Ferreira de Melo, Thais Regina
    Rodrigues Sartori, Geraldo
    Martins da Silva, Joao Herminio
    Chin, Chung Man
    Dos Santos, Jean Leandro
    PHARMACEUTICALS, 2022, 15 (10)
  • [30] HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment
    Colussi, Claudia
    Mozzetta, Chiara
    Gurtner, Aymone
    Illi, Barbara
    Rosati, Jessica
    Straino, Stefania
    Ragone, Gianluca
    Pescatori, Mario
    Zaccagnini, Germana
    Antonini, Annalisa
    Minetti, Giulia
    Martelli, Fabio
    Piaggio, Giulia
    Gallinari, Paola
    Steinkulher, Christian
    Clementi, Emilio
    Dell'Aversana, Carmela
    Altucci, Lucia
    Mai, Antonello
    Capogrossi, Maurizio C.
    Puri, Pier Lorenzo
    Gaetano, Carlo
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (49) : 19183 - 19187